Teacher Retirement System of Texas Sells 116,864 Shares of Solventum Corporation $SOLV

Teacher Retirement System of Texas cut its holdings in Solventum Corporation (NYSE:SOLV) by 85.2% in the third quarter, Holdings Channel.com reports. The fund owned 20,367 shares of the company’s stock after selling 116,864 shares during the quarter. Teacher Retirement System of Texas’ holdings in Solventum were worth $1,487,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of SOLV. CYBER HORNET ETFs LLC acquired a new stake in shares of Solventum in the 2nd quarter valued at $28,000. Barrett & Company Inc. raised its holdings in Solventum by 206.2% during the second quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock valued at $30,000 after buying an additional 268 shares in the last quarter. IMG Wealth Management Inc. acquired a new stake in shares of Solventum in the second quarter worth about $31,000. MUFG Securities EMEA plc acquired a new stake in shares of Solventum in the second quarter worth about $31,000. Finally, State of Wyoming bought a new stake in shares of Solventum during the 2nd quarter worth about $33,000.

Solventum Stock Performance

Shares of NYSE SOLV opened at $76.87 on Friday. The firm has a market capitalization of $13.33 billion, a price-to-earnings ratio of 8.86, a PEG ratio of 7.03 and a beta of 0.34. Solventum Corporation has a one year low of $60.70 and a one year high of $88.20. The business has a fifty day simple moving average of $81.52 and a 200 day simple moving average of $75.82. The company has a current ratio of 1.50, a quick ratio of 1.14 and a debt-to-equity ratio of 1.03.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Thursday, November 6th. The company reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.43 by $0.07. The firm had revenue of $2.10 billion during the quarter, compared to analysts’ expectations of $2.05 billion. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The company’s revenue for the quarter was up .7% compared to the same quarter last year. During the same quarter last year, the company earned $1.64 earnings per share. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. Sell-side analysts expect that Solventum Corporation will post 6.58 EPS for the current year.

Solventum announced that its Board of Directors has authorized a share buyback plan on Thursday, November 20th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the company to purchase up to 7.5% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board believes its stock is undervalued.

Analyst Ratings Changes

Several equities research analysts recently weighed in on SOLV shares. Zacks Research lowered Solventum from a “strong-buy” rating to a “hold” rating in a report on Monday, December 1st. Mizuho set a $100.00 price target on shares of Solventum and gave the company an “outperform” rating in a research report on Tuesday, January 20th. Piper Sandler restated an “overweight” rating on shares of Solventum in a research note on Wednesday, December 17th. UBS Group reaffirmed a “neutral” rating on shares of Solventum in a report on Friday, November 21st. Finally, Stifel Nicolaus lifted their target price on shares of Solventum from $88.00 to $105.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Seven analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $90.83.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.